Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli

Rodríguez-Villodres, Ángel; Linares, Alicia Gutiérrez; Gálvez-Benítez, Lydia; Pachón, Jerónimo; Lepe, José Antonio Suárez; Smani, Younes

doi:10.1128/spectrum.00801-21

Cited by 10 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To provide a highly sensitive, rapid and cost-effective alternative method, we developed a diagnostic test based on MALDI-TOF MS and Clover Bioanalytical Software, called MALDIpiptaz, for the detection of ESRI developer- and P/T-resistant isolates of E. coli . After initial validation using a well-characterized collection of ESRI developer-, P/T-susceptible and P/T-resistant isolates [ 4 , 19 ], we performed a prospective evaluation on E. coli isolated from bloodstream and intraabdominal samples during which the Clover Bioanalytical Software and the MALDIpiptaz test precisely detected all ESRI developer- and P/T-resistant isolates.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, this differentiation between both cell populations is only determined by molecular methods (real-time PCR and WGS) that have detected regulation in bla TEM genes [ 4 , 6 , 8 ]. Of note, the ESRI developer’s isolates harboured one or more different beta-lactamase genes such as TEM, SHV and OXA-1 [ 19 ]. These molecular methods are costly, time-consuming and not easy to perform in clinical microbiology laboratories.…”

Section: Discussionmentioning

confidence: 99%

“…We used a collection of non-duplicated 248 E. coli isolates, including 54 P/T-resistant and 81 ESRI developer isolates [ 19 ]. The 74 P/T-susceptible E. coli isolates were wild-type .…”

Section: Methodsmentioning

confidence: 99%

“…The bla TEM , bla OXA−1 , and bla SHV genes and ESRI were determined and analyzed in all studied isolates by PCR and ESRI test, respectively, as we previously described [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

“…Recently, a biochemical test, i.e. the ESRI test, was developed to detect P/T-resistant E. coli isolates and P/T-susceptible E. coli isolates but with capability for ESRI development (ESRI developers) [ 19 ]. This test is semirapid (within 3 h after bacterial identification by MALDI-MS) and easy to perform, but it is designed only for E. coli growing in haemoculture bottles rather than agar plates.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test

Villodres

Benítez

Arroyo

et al. 2022

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

Background The excessive use of piperacillin/tazobactam (P/T) has promoted the emergence of P/T-resistant Enterobacterales . We reported that in Escherichia coli , P/T contributes to the development of extended-spectrum resistance to β-lactam/β-lactamase inhibitor (BL/BLI) (ESRI) in isolates that are P/T susceptible but have low-level resistance to BL/BLI. Currently, the detection of P/T resistance relying on conventional methods is time-consuming. To overcome this issue, we developed a cost-effective test based on MALDI-MS technology, called MALDIpiptaz, which aims to detect P/T resistance and ESRI developers in E. coli . Methods We used automated Clover MS Data Analysis software to analyse the protein profile spectra obtained by MALDI-MS from a collection of 248 E. coli isolates (91 P/T-resistant, 81 ESRI developers and 76 P/T-susceptible). This software allowed to preprocess all the spectra to build different peak matrices that were analysed by machine learning algorithms. Results We demonstrated that MALDIpiptaz can efficiently and rapidly (15 min) discriminate between P/T-resistant, ESRI developer and P/T-susceptible isolates and allowed the correct classification between ESRI developers from their isogenic resistance to P/T. Conclusion The combination of excellent performance and cost-effectiveness are all desirable attributes, allowing the MALDIpiptaz test to be a useful tool for the rapid determination of P/T resistance in clinically relevant E. coli isolates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…We used a collection of non-duplicated 248 E. coli isolates, including 54 P/T-resistant and 81 ESRI developer isolates [ 19 ]. The 74 P/T-susceptible E. coli isolates were wild-type .…”

Section: Methodsmentioning

confidence: 99%

“…The bla TEM , bla OXA−1 , and bla SHV genes and ESRI were determined and analyzed in all studied isolates by PCR and ESRI test, respectively, as we previously described [ 19 ].…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test

Villodres

Benítez

Arroyo

et al. 2022

Emerging Microbes & Infections

Self Cite

View full text Add to dashboard Cite

show abstract

Role of blaTEM and OmpC in the piperacillin-tazobactam resistance evolution by E. coli in patients with complicated intra-abdominal infection

Gálvez-Benítez

Rosa

Rodríguez-Villodres

et al. 2023

Journal of Infection

View full text Add to dashboard Cite

Prediction of antimicrobial resistance in Klebsiella pneumoniae using genomic and metagenomic next-generation sequencing data

Zhou,

Yang,

Chen

et al. 2024

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Objectives Klebsiella pneumoniae is a significant pathogen with increasing resistance and high mortality rates. Conventional antibiotic susceptibility testing methods are time-consuming. Next-generation sequencing has shown promise for predicting antimicrobial resistance (AMR). This study aims to develop prediction models using whole-genome sequencing data and assess their feasibility with metagenomic next-generation sequencing data from clinical samples. Methods On the basis of 4170 K. pneumoniae genomes, the main genetic characteristics associated with AMR were identified using a LASSO regression model. Consequently, the prediction model was established, validated and optimized using clinical isolate read simulation sequences. To evaluate the efficacy of the model, clinical specimens were collected. Results Four predictive models for amikacin, ciprofloxacin, levofloxacin and piperacillin/tazobactam, initially had positive predictive values (PPVs) of 90%, 85%, 84% and 94%, respectively, when they were originally constructed. When applied to clinical specimens, their PPVs increased to 96%, 96%, 95% and 100%, respectively. Meanwhile, there were negative predictive values (NPVs) of 100% for ciprofloxacin and levofloxacin, and ‘not applicable’ (NA) for amikacin and piperacillin/tazobactam. Our method achieved antibacterial phenotype classification accuracy rates of 96.08% for amikacin, 96.15% for ciprofloxacin, 95.31% for levofloxacin and 100% for piperacillin/tazobactam. The sequence-based prediction antibiotic susceptibility testing (AST) reported results in an average time of 19.5 h, compared with the 67.9 h needed for culture-based AST, resulting in a significant reduction of 48.4 h. Conclusions These preliminary results demonstrated that the performance of prediction model for a clinically significant antimicrobial–species pair was comparable to that of phenotypic methods, thereby encouraging the expansion of sequence-based susceptibility prediction and its clinical validation and application.

show abstract

Semirapid Detection of Piperacillin/Tazobactam Resistance and Extended-Spectrum Resistance to β-Lactams/β-Lactamase Inhibitors in Clinical Isolates of Escherichia coli

Abstract: TZP is a BL/BLI recommended for the empirical treatment of severe infections. The excessive use of TZP has promoted the emergence of TZP-resistant Escherichia coli isolates.

Cited by 10 publications

References 23 publications

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test

Role of blaTEM and OmpC in the piperacillin-tazobactam resistance evolution by E. coli in patients with complicated intra-abdominal infection

Prediction of antimicrobial resistance in Klebsiella pneumoniae using genomic and metagenomic next-generation sequencing data

Contact Info

Product

Resources

About